代谢组学在糖尿病肾病研究中的应用进展  

Advances of metabolomics in diabetic nephropathy

作　　者：赵黎君[1] 刘芳[1] ZHAO Lijun;LIU Fang(Department of Nephrology,West China Hospital of Sichuan University,Chengdu,Sichuan 610041,China)

机构地区：[1]四川大学华西医院肾脏内科

出　　处：《重庆医学》2019年第17期2996-3000,共5页Chongqing medicine

基　　金：国家自然科学基金项目(81670662)

摘　　要：糖尿病肾病(DN)是糖尿病常见的微血管并发症之一,也是终末期肾脏病最主要的原因。代谢组学作为系统生物学的四大技术之一,可以实时监测组织、体液中已经发生的内源性小分子代谢产物的变化,单用或联合其他组学在DN的早期诊断、疗效、预后判断等方面均有应用。本文就代谢组学在DN的研究进行总结综述。Diabetic nephropathy(DN)is one of the most common microvascular complications of diabetes mellitus.It is also the leading cause of end-stage renal disease.As one of the four technologies in the field of systems biology,metabolomics analysis is a process of monitoring all exogenous metabolites changes in tissues or biofluids with time.The usage of metabolomics alone or with other omics offers the potential approach to improvement in early diagnosis,therapeutic effect and prognosis in DN.In this article,we reviewed the recent progress of metabolomics in DN.

关 键 词：糖尿病肾病 代谢组学 生物标志物 脂质 氨基酸 

分 类 号：R446.9[医药卫生—诊断学]